Cryoport, Inc. (NASDAQ:CYRX) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $11.50.

Several research analysts recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price target on shares of Cryoport in a research report on Wednesday, March 5th. Guggenheim assumed coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a "buy" rating and a $11.00 price target on the stock.

Cryoport Stock Up 5.9 %

Shares of NASDAQ CYRX opened at $7.04 on Thursday. The firm's 50-day simple moving average is $7.17 and its 200 day simple moving average is $7.52. The company has a market cap of $347.99 million, a price-to-earnings ratio of -2.08 and a beta of 1.67. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport has a 12-month low of $4.58 and a 12-month high of $20.11.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter last year, the company earned ($0.29) EPS. On average, research analysts expect that Cryoport will post -0.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after acquiring an additional 2,120 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Cryoport in the 4th quarter valued at approximately $51,000. Avanza Fonder AB acquired a new stake in shares of Cryoport in the 4th quarter valued at approximately $64,000. Quarry LP acquired a new stake in shares of Cryoport in the 4th quarter valued at approximately $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cryoport in the 3rd quarter valued at approximately $82,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads